Therapeutics(LENZ),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

LENZ Therapeutics

Trading 11-05 09:32:20 EST

28.53

+0.10

+0.35%

High29.23	Low28.43	Vol19.32K
Open29.23	D1 Closing28.43	Amplitude2.81%
Mkt Cap784.48M	Tradable Cap356.98M	Total Shares27.50M
T/O561.54K	T/O Rate0.15%	Tradable Shares12.51M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"LENZ","market":"US","secType":"STK","nameCN":"Therapeutics","latestPrice":28.53,"timestamp":1730817131151,"preClose":28.43,"halted":0,"volume":19323,"delay":0,"floatShares":12512401,"shares":27496665,"eps":-4.263813,"marketStatus":"Trading","change":0.1,"latestTime":"11-05 09:32:20 EST","open":29.23,"high":29.23,"low":28.43,"amount":561538.862658,"amplitude":0.028139,"askPrice":29.24,"askSize":333,"bidPrice":28.5,"bidSize":30,"shortable":3,"etf":0,"ttmEps":-4.263813,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Market Trading","tradingStatus":3,"beginTime":1730840400000},"marketStatusCode":2,"adr":0,"listingDate":1624593600000,"exchange":"NASDAQ","adjPreClose":28.43,"preHourTrading":{"tag":"盘前","latestPrice":29.18,"preClose":28.43,"latestTime":"09:29 EST","volume":1078,"amount":31850.561049999997,"timestamp":1730816999999},"postHourTrading":{"tag":"盘后","latestPrice":28.43,"preClose":28.43,"latestTime":"16:58 EST","volume":2669,"amount":75885.27,"timestamp":1730757525501},"volumeRatio":18.227711},"requestUrl":"/m/hq/s/LENZ","defaultTab":"news","newsList":[{"id":"2481190507","title":"Candel Therapeutics to present data at SITC annual meeting on CAN-3110","url":"https://stock-news.laohu8.com/highlight/detail?id=2481190507","media":"TIPRANKS","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481190507?lang=en_us&edition=fundamental","pubTime":"2024-11-05 22:20","pubTimestamp":1730816420,"startTime":"0","endTime":"0","summary":"Candel Therapeutics (CADL) announced preclinical results and therapeutic potential of CAN-3110 in the Ras-Raf pathway altered melanoma model. The d...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/candel-therapeutics-to-present-data-at-sitc-annual-meeting-on-can-3110?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/candel-therapeutics-to-present-data-at-sitc-annual-meeting-on-can-3110?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4139","LENZ","BK4595","BK4170","BK4526","CADL"],"gpt_icon":0},{"id":"2481500845","title":"TScan Therapeutics Announces Upcoming Oral Presentation of Data from the ALLOHA™ Phase 1 Heme Trial at the 66th American Society of Hematology Annual Meeting and Exposition","url":"https://stock-news.laohu8.com/highlight/detail?id=2481500845","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481500845?lang=en_us&edition=fundamental","pubTime":"2024-11-05 22:15","pubTimestamp":1730816100,"startTime":"0","endTime":"0","summary":"All TSC-treated patients were relapse-free and MRD negative as of data cutoff TSC-100 and TSC-101 demonstrate the potential to reduce relapse rates and increase relapse-free survival in patients with ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/05/2975010/0/en/TScan-Therapeutics-Announces-Upcoming-Oral-Presentation-of-Data-from-the-ALLOHA-Phase-1-Heme-Trial-at-the-66th-American-Society-of-Hematology-Annual-Meeting-and-Exposition.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KOL","BK4533","LU2355687059.USD","BK4585","BK4109","ALL","BK4588","LU2463526074.USD","RIC","BK4139","AFG","LENZ","LU0985320562.USD","LU1699723380.USD","BK4117","LU1571399168.USD","ASH","BK4107"],"gpt_icon":0},{"id":"2481502726","title":"Beam Therapeutics' Q3 Net Loss Narrows, Revenue Falls","url":"https://stock-news.laohu8.com/highlight/detail?id=2481502726","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481502726?lang=en_us&edition=fundamental","pubTime":"2024-11-05 22:11","pubTimestamp":1730815861,"startTime":"0","endTime":"0","summary":"Beam Therapeutics  reported a Q3 net loss Tuesday of $1.17 per share, narrowing from a loss of $1.22 a year earlier.Analysts polled by Capital IQ expected a loss of $1.15.License and collaboration revenue for the quarter ended Sept. 30 was $14.3 million, down from $17.2 million a year earlier.Analysts surveyed by Capital IQ expected $14.1 million.The company said it had $925.8 million in cash, cash equivalents and marketable securities as of Sept. 30 to fund its operations into 2027.Shares of the company were down over 10% in recent premarket activity.Price: 21.60, Change: -2.76, Percent Change: -11.33","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BEAM","LENZ"],"gpt_icon":0},{"id":"2481507907","title":"Century Therapeutics reports Q3 EPS (37c), consensus (45c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2481507907","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481507907?lang=en_us&edition=fundamental","pubTime":"2024-11-05 22:10","pubTimestamp":1730815856,"startTime":"0","endTime":"0","summary":"Reports Q3 revenue $791,000, consensus $2.02M. “Broadening our strategic focus in autoimmune indications to include idiopathic inflammatory myopath...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/century-therapeutics-reports-q3-eps-37c-consensus-45c?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/century-therapeutics-reports-q3-eps-37c-consensus-45c?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IPSC","CNBKA","LENZ"],"gpt_icon":0},{"id":"2481021445","title":"BRIEF-Century Therapeutics Q3 Net Income USD -31.226 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2481021445","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481021445?lang=en_us&edition=fundamental","pubTime":"2024-11-05 22:05","pubTimestamp":1730815545,"startTime":"0","endTime":"0","summary":"Nov 05 (Reuters) - Century Therapeutics Q3 operating expenses USD 35.58 million. * Q3 operating income USD -34.789 million * Q3 basic EPS USD -0.37 * outlook FY operating expenses USD 150-160 million","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4505","BK4139","USD","LENZ","IPSC","CNBKA"],"gpt_icon":0},{"id":"2481122502","title":"Press Release: Century Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2481122502","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481122502?lang=en_us&edition=fundamental","pubTime":"2024-11-05 22:05","pubTimestamp":1730815500,"startTime":"0","endTime":"0","summary":"-- Expansion of Phase 1 CALiPSO-1 trial of CNTY-101 in autoimmune disease to include diffuse cutaneous systemic sclerosis and idiopathic inflammatory myopathy --. -- Overall response rate  of 83% observed at CNTY-101 Dose Level 3B alongside a favorable safety profile in patients with r/r B-cell lymphomas in Phase 1 ELiPSE-1 study --. -- CNTY-101 shows persistence upon repeated cell dosing at Dose Level 3B, consistent with the anticipated protective activity of Century's proprietary Allo-Evasion technology --. -- Ended third quarter 2024 with cash, cash equivalents, and investments of $244.7 million; organizational efficiencies extend expected cash runway into second half of 2026 --. PHILADELPHIA, Nov. 05, 2024  -- Century Therapeutics, Inc. , an innovative biotechnology company developing induced pluripotent stem cell -derived cell therapies in immuno-oncology and autoimmune disease, today reported financial results and business highlights for the third quarter ended September 30, 2024","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","CRS","03160","IE00B66KJ199.SGD","BK4555","BK4006","BK4539","TM","IE00B7SZL793.SGD","CNBKA","SLE","LENZ","BK4099","BK4588","IE0031619046.USD","IIM","BK4077","BK4505","BK4139","IE00B19Z4B17.USD","IPSC"],"gpt_icon":1},{"id":"2481021795","title":"CRISPR Therapeutics Q3 EPS $(1.01) Beats $(1.42) Estimate, Sales $602.00K","url":"https://stock-news.laohu8.com/highlight/detail?id=2481021795","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481021795?lang=en_us&edition=fundamental","pubTime":"2024-11-05 22:04","pubTimestamp":1730815453,"startTime":"0","endTime":"0","summary":"CRISPR Therapeutics Q3 EPS $(1.01) Beats $(1.42) Estimate, Sales $602.00K","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/11/41745392/crispr-therapeutics-q3-eps-1-01-beats-1-42-estimate-sales-602-00k","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRSP","LENZ"],"gpt_icon":0},{"id":"2481850782","title":"C4 Therapeutics to Present Data from the Ongoing Phase 1/2 Trial of Cemsidomide in Multiple Myeloma and Non-Hodgkin’s Lymphoma at the American Society of Hematology (ASH) Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2481850782","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481850782?lang=en_us&edition=fundamental","pubTime":"2024-11-05 22:00","pubTimestamp":1730815200,"startTime":"0","endTime":"0","summary":"C4T to Host Webcast on Sunday, December 8, 2024 at 2 PM PT (5 PM ET)WATERTOWN, Mass., Nov.  05, 2024  (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/05/2974973/0/en/C4-Therapeutics-to-Present-Data-from-the-Ongoing-Phase-1-2-Trial-of-Cemsidomide-in-Multiple-Myeloma-and-Non-Hodgkin-s-Lymphoma-at-the-American-Society-of-Hematology-ASH-Annual-Meet.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2463526074.USD","BK4139","AFG","ASH","BK4109","LENZ","BK4107","CCCC","BK4117"],"gpt_icon":0},{"id":"2481507382","title":"Century Therapeutics Announces Upcoming Poster Presentations at the 2024 American Society of Hematology (ASH) Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2481507382","media":"GlobeNewswire","labels":["Important Conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481507382?lang=en_us&edition=fundamental","pubTime":"2024-11-05 22:00","pubTimestamp":1730815200,"startTime":"0","endTime":"0","summary":"– Company to share preclinical data across diverse pipeline of iNK, γδ iT, and αβ iT cell therapy programs for oncology and autoimmune disease  –。– Preclinical data on development of iPSC-derived CD4+ and CD8+ CAR T cells that demonstrate function comparable to primary αβ CAR-T cells, allowing for control of tumors in vivo without the need for exogenous or engineered cytokines –。– Posters include demonstration of advances in gene editing and transgene design that enable greater control and improved functionality of iPSC derived immune cells –。PHILADELPHIA, Nov. 05, 2024  -- Century Therapeutics , an innovative biotechnology company developing induced pluripotent stem cell -derived cell therapies in immuno-oncology and autoimmune disease, today announced that preclinical data from the Company’s iPSC-derived cell therapy platform will be presented in five posters at the 2024 ASH Annual Meeting to be held in San Diego, CA from December 7-10, 2024.Optimizing Chimeric Antigen Receptor Endod","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/97dqWeswHs8cfp6vbFoonQ--~B/aD00MjI7dz0xNDE3O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/1e32bfaefbccf3446e603039ed3861b6","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/97dqWeswHs8cfp6vbFoonQ--~B/aD00MjI7dz0xNDE3O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/1e32bfaefbccf3446e603039ed3861b6"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/century-therapeutics-announces-upcoming-poster-140000507.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Important Conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4022","BK4139","BK4505","BK4539","BK4109","BK4117","AFG","LENZ","CNBKA","BK4230","LU2463526074.USD","IPSC","CAR","BK4107","ASH"],"gpt_icon":1},{"id":"2481507358","title":"Keros Therapeutics to Present at the 66th American Society of Hematology Annual Meeting and Exposition","url":"https://stock-news.laohu8.com/highlight/detail?id=2481507358","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481507358?lang=en_us&edition=fundamental","pubTime":"2024-11-05 22:00","pubTimestamp":1730815200,"startTime":"0","endTime":"0","summary":"LEXINGTON, Mass., Nov. 05, 2024  -- Keros Therapeutics, Inc.  , a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta  family of proteins, today announced that three abstracts will be presented from its hematology program at the 66th American Society of Hematology  Annual Meeting and Exposition to be held in person and virtually from December 7 through 10, 2024. Keros will be presenting additional results from its two ongoing Phase 2 clinical trials of elritercept , one in patients with very low-, low-, or intermediate-risk myelodysplastic syndrome  and one in patients with myelofibrosis .The following abstracts were posted to the ASH website on November 5, 2024, 9:00 a.m. Eastern time.“Improvements in Hematological Parameters and Quality of Life  with Elritercept : Results from an Ongoing Phase 2 Trial in P","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/ljBZsb8HTr.P.ouI20ICHg--~B/aD02MzU7dz0xNzg5O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/32d571da8b4f8883a54fc4e04672f17a","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/ljBZsb8HTr.P.ouI20ICHg--~B/aD02MzU7dz0xNzg5O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/32d571da8b4f8883a54fc4e04672f17a"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/keros-therapeutics-present-66th-american-140000070.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4117","AFG","LENZ","BK4139","BK4107","KROS"],"gpt_icon":0},{"id":"2481502437","title":"Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024 in One Oral Presentation and Three Poster Presentations","url":"https://stock-news.laohu8.com/highlight/detail?id=2481502437","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481502437?lang=en_us&edition=fundamental","pubTime":"2024-11-05 22:00","pubTimestamp":1730815200,"startTime":"0","endTime":"0","summary":"LONDON, Nov. 05, 2024  -- Autolus Therapeutics plc, a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announces the online publication of four abstracts submitted to the American Society of Hematology  Annual Meeting, to be held from December 7-10, 2024, in San Diego.“The FELIX study’s rich data set continues to provide important information in shaping our understanding of the use of obe-cel to treat adult r/r B-ALL patients,” said Dr. Christian Itin, Chief Executive Officer of Autolus. “We are presenting additional data at ASH that suggests deep molecular remission that may predict better outcomes; shows the impact of bridging therapy on outcomes; highlights the costs associated with managing CRS and ICANS; and how using hematotoxicity scores can help identify patients who are more likely benefit from treatment with obe-cel.”Summary: Patients in the FELIX study received bridging therapy  (chemotherapy with or without Inotuzumab ozoga","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/DQ6UN6ogBYGtAppDXG55hg--~B/aD05Mjt3PTM5MjthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/49d8c6397e759338078474305555c4a1","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/DQ6UN6ogBYGtAppDXG55hg--~B/aD05Mjt3PTM5MjthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/49d8c6397e759338078474305555c4a1"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/autolus-therapeutics-present-clinical-data-140000381.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AFG","BK4022","BK4583","LENZ","BK4117","BK4097","ICU","IE00B66KJ199.SGD","IE0031619046.USD","BK4107","ASH","AUTL","BK4568","BK4179","HT","IE00B19Z4B17.USD","LU2463526074.USD","UCL","BK4109","IE00B7SZL793.SGD","INO","CAR","BK4139","BK4082","BK4218","NGS","BK4006","BK4230","BK4181","CRS","BT","BK4132","OS"],"gpt_icon":0},{"id":"2481295502","title":"Candel Therapeutics to Present Preclinical Data at SITC Annual Meeting Showing Promise for CAN-3110 in Melanoma, Signaling Potential Indication Expansion Beyond Recurrent High-Grade Glioma","url":"https://stock-news.laohu8.com/highlight/detail?id=2481295502","media":"GlobeNewswire","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481295502?lang=en_us&edition=fundamental","pubTime":"2024-11-05 22:00","pubTimestamp":1730815200,"startTime":"0","endTime":"0","summary":"Abstract selected as poster presentation during the Society for Immunotherapy of Cancer  Annual Meeting shows potent antitumor activity of CAN-3110 in preclinical models of melanoma. CAN-3110's activity is designed to be conditional to the expression of Nestin in cancer cells and is associated with dual activity for oncolysis and immune activation. Findings support potential indication expansion for CAN-3110 beyond high-grade glioma into melanoma, another Nestin-expressing solid tumor. Data presented at SITC showed potent monotherapy, anti-tumor activity of CAN-3110 in both in vitro human cell lines and in vivo murine models of melanoma. In vivo, CAN-3110 exhibited tumor-specific cytotoxicity with dose-dependent inhibition of tumor growth and tumor regression observed in a subset of tumors treated with a high dose of CAN-3110. Cytotoxic activity in melanoma-bearing mice was associated with systemic immune activation and increased proliferation of circulating T cells, mirroring the effe","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/OVaui3MA0nAIzdRidF5_Jg--~B/aD0xNTE4O3c9MzMyNTthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/0967bb083514f87a91b7c0ba0cacf3b2","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/OVaui3MA0nAIzdRidF5_Jg--~B/aD0xNTE4O3c9MzMyNTthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/0967bb083514f87a91b7c0ba0cacf3b2"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/candel-therapeutics-present-preclinical-data-140000708.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4080","BK4231","LENZ","BK4526","BK4178","BK4595","BK4170","BK4539","BK4585","BK4139","SITC","BK4588","CADL"],"gpt_icon":1},{"id":"2481750158","title":"Press Release: Atossa Therapeutics Appoints Claudia Lopez, DVM, MSc, as Vice President, Clinical Product Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2481750158","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481750158?lang=en_us&edition=fundamental","pubTime":"2024-11-05 21:30","pubTimestamp":1730813400,"startTime":"0","endTime":"0","summary":"Dr. Lopez Brings 20+ Years of Global Clinical Development and Leadership to Support Atossa's Mission in Developing Innovative Breast Cancer Therapies. SEATTLE, Nov. 05, 2024  -- Atossa Therapeutics, Inc.  , today announced the appointment of Claudia Lopez, DVM, MSc, as its new Vice President, Clinical Product Development. Dr. Lopez brings more than two decades of clinical development and strategic expertise to Atossa, including leadership roles in global clinical programs across immunology, oncology, and metabolic disease. Atossa Therapeutics is a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer.\"We are pleased to welcome Dr. Lopez to the Atossa team. Her extensive experience in clinical development, particularly her strategic acumen in guiding multifaceted clinical trials, aligns perfectly with our mission to bring transformative treatments to women with breast cancer,\" said Dr. Steven Quay, Chief Executive Officer of Atossa Therapeutics. \"Cla","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LENZ","ATOS","Z","BK4548","BK4588","BK4585","BK4551","BK4079"],"gpt_icon":0},{"id":"2481509446","title":"William Blair Initiates Camp4 Therapeutics at Outperform","url":"https://stock-news.laohu8.com/highlight/detail?id=2481509446","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481509446?lang=en_us&edition=fundamental","pubTime":"2024-11-05 21:19","pubTimestamp":1730812766,"startTime":"0","endTime":"0","summary":"(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www.mtnewswires.com/contact-us)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CAMP","LENZ"],"gpt_icon":0},{"id":"2481094455","title":"Piper Sandler Initiates Camp4 Therapeutics at Overweight With $18 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2481094455","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481094455?lang=en_us&edition=fundamental","pubTime":"2024-11-05 21:19","pubTimestamp":1730812757,"startTime":"0","endTime":"0","summary":"Piper Sandler Initiates Camp4 Therapeutics at Overweight With $18 Price Target","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CAMP","LENZ"],"gpt_icon":0},{"id":"2481094105","title":"Leerink Partners Initiates Camp4 Therapeutics at Outperform With $17 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2481094105","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481094105?lang=en_us&edition=fundamental","pubTime":"2024-11-05 21:19","pubTimestamp":1730812741,"startTime":"0","endTime":"0","summary":"Leerink Partners Initiates Camp4 Therapeutics at Outperform With $17 Price Target","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CAMP","LENZ"],"gpt_icon":0},{"id":"2481857509","title":"BRIEF-Starlight Therapeutics Announces Inaugural Members Of Scientific Advisory Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2481857509","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481857509?lang=en_us&edition=fundamental","pubTime":"2024-11-05 21:14","pubTimestamp":1730812477,"startTime":"0","endTime":"0","summary":"Nov 5 (Reuters) - Lantern Pharma Inc   :   * STARLIGHT THERAPEUTICS ANNOUNCES INAUGURAL MEMBERS OF SCIENTIFIC ADVISORY BOARDSource text:    Further company coverage:    (Reuters.Briefs@thomsonreuters.com)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","LTRN","BK4139"],"gpt_icon":0},{"id":"2481504477","title":"Protagenic Therapeutics Announces Closing of Private Placement for Aggregate Gross Proceeds of $1.275 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2481504477","media":"ACCESSWIRE","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481504477?lang=en_us&edition=fundamental","pubTime":"2024-11-05 21:12","pubTimestamp":1730812320,"startTime":"0","endTime":"0","summary":"NEW YORK, NY / ACCESSWIRE / November 5, 2024 / Protagenic Therapeutics, Inc.  , a leader in biopharmaceutical innovation, announced today that on November 4, 2024 it closed its previously announced private placement pursuant to a purchase agreement  for the purchase and sale of an aggregate of 1,948,295 shares of common stock, series A common stock purchase warrants to purchase an aggregate of 1,948,295 shares of common stock, with an exercise price of $0.64 per share, which are exercisable on the trading day immediately following the Stockholder Approval Date  for a term of eighteen  months from the Stockholder Approval Date, and series B common stock purchase warrants to purchase an aggregate of 1,948,295 shares of common stock with an exercise price of $0.64 per share, which are exercisable on the trading day immediately following the Stockholder Approval Date for a term of five  years from the Stockholder Approval Date. The purchase price of each share of common stock and associate","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/protagenic-therapeutics-announces-closing-private-131200289.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LENZ","PTIXW","BK4139","PTIX"],"gpt_icon":0},{"id":"2481506005","title":"Starlight Therapeutics Announces Inaugural Members of Scientific Advisory Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2481506005","media":"Business Wire","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481506005?lang=en_us&edition=fundamental","pubTime":"2024-11-05 21:00","pubTimestamp":1730811600,"startTime":"0","endTime":"0","summary":"DALLAS, November 05, 2024----Starlight Therapeutics, a wholly-owned subsidiary of Lantern Pharmaceuticals , formed to develop transformative CNS cancer treatments with AI-powered innovation, announced today the formation of a Scientific Advisory Board  to support the development of lead compound STAR-001. The inaugural SAB will work closely with Starlight’s management team to provide strategic guidance and critical expert insights into the development of STAR-001 in CNS and brain tumors for both children and adults.\"The establishment of the SAB represents a significant advancement for Starlight, and we are honored to be joined by such accomplished scientific experts. We look forward to drawing upon the deep subject matter expertise of Drs. Berger, DeAngelis, Grossman and Laterra, to shape the development path of STAR-001,\" said Dr. Marc Chamberlain, M.D., Starlight’s Chief Medical Officer. \"We also extend congratulations to Drs. Berger and Grossman on being recipients of the prestigiou","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/3lYwz6JWw6lih0fUkzJpOQ--~B/aD0yNzQ7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/8032aedd176fa65703ac7c4cdc0808a6","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/3lYwz6JWw6lih0fUkzJpOQ--~B/aD0yNzQ7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/8032aedd176fa65703ac7c4cdc0808a6"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/starlight-therapeutics-announces-inaugural-members-130000701.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","LENZ","BK4178","LTRN","AAN"],"gpt_icon":1},{"id":"2481166506","title":"Black Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2481166506","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481166506?lang=en_us&edition=fundamental","pubTime":"2024-11-05 21:00","pubTimestamp":1730811600,"startTime":"0","endTime":"0","summary":"Announced encouraging initial Phase 2 data of BDTX-1535 in patients with recurrent EGFRm NSCLC with a broad spectrum of classical, non-classical, and C797S resistance mutations in September 2024. Presented real-world treatment practices and patient outcomes in newly diagnosed NSCLC patients with non-classical EGFR mutations at the 2024 ESMO Congress. Clinical updates of BDTX-1535 in EGFRm NSCLC and regulatory feedback expected in Q1 2025. Cash, cash equivalents, and investments of $112.7 million as of September30, 2024; expected to be sufficient to fund operations into Q2 of 2026. In September 2024, Black Diamond presented a poster analyzing real-world treatment outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations  at the 2024 European Society for Medical Oncology  Congress. The analyses revealed the presence of a broad spectrum of NCMs, including PACC mutations, and allowed association with real-world treatment practices and therapeutic outcomes. Findings furt","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/BXvxt76gxDkYRmwEchGbew--~B/aD0yNTc7dz04Njc7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/518a8bb61ba367794514902f3e7e8df5","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/BXvxt76gxDkYRmwEchGbew--~B/aD0yNTc7dz04Njc7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/518a8bb61ba367794514902f3e7e8df5"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/black-diamond-therapeutics-reports-third-130000914.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BDTX","BK4139","BDE","PR","BK4213","LENZ"],"gpt_icon":0}],"profile":{"websiteUrl":"http://lenz-tx.com","stockEarnings":[{"period":"1week","weight":-0.0025},{"period":"1month","weight":0.1028},{"period":"3month","weight":0.2072},{"period":"6month","weight":0.7571},{"period":"1year","weight":0.7658},{"period":"ytd","weight":0.5502}],"compareEarnings":[{"period":"1week","weight":-0.019},{"period":"1month","weight":-0.0055},{"period":"3month","weight":0.0913},{"period":"6month","weight":0.1017},{"period":"1year","weight":0.3108},{"period":"ytd","weight":0.1988}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"TherapeuticsMD, Inc. operates as a pharmaceutical company in the United States. It has a license  agreement with Mayne Pharma to commercialize the IMVEXXY,BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands. The company sells its prescription pharmaceutical products and prenatal vitamin products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.187611},{"month":2,"riseRate":0.666667,"avgChangeRate":0.15153},{"month":3,"riseRate":0,"avgChangeRate":-0.19103},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.06634},{"month":5,"riseRate":0,"avgChangeRate":-0.187229},{"month":6,"riseRate":0.666667,"avgChangeRate":0.07217},{"month":7,"riseRate":0.5,"avgChangeRate":0.062427},{"month":8,"riseRate":0.25,"avgChangeRate":-0.053734},{"month":9,"riseRate":0.5,"avgChangeRate":-0.017856},{"month":10,"riseRate":0.75,"avgChangeRate":0.006056},{"month":11,"riseRate":0.5,"avgChangeRate":-0.080031},{"month":12,"riseRate":0.666667,"avgChangeRate":0.157581}],"exchange":"NASDAQ","name":"Therapeutics","nameEN":"Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Therapeutics(LENZ),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Therapeutics(LENZ) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Therapeutics,LENZ,Therapeutics股票,Therapeutics股票老虎,Therapeutics股票老虎国际,Therapeutics行情,Therapeutics股票行情,Therapeutics股价,Therapeutics股市,Therapeutics股票价格,Therapeutics股票交易,Therapeutics股票购买,Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Therapeutics(LENZ),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Therapeutics(LENZ) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}